Le Lézard
Classified in: Health
Subject: EXE

Information Update - Health Canada is advising Canadians of the potential limitations when using test strips to detect fentanyl


OTTAWA, Dec. 13, 2017 /CNW/ - Health Canada is advising Canadians of the potential limitations when using test strips to detect fentanyl in street drugs.

A preliminary study undertaken by Health Canada indicated that false negatives could occur when using fentanyl-detection test strips. A false negative would be a test result that does not detect the fentanyl in a drug sample even though it does contain fentanyl. A false negative could lead to a false sense of security which may result in overdose or death. This is particularly true for people who may choose to use drugs alone or without visiting a supervised consumption site where emergency help is immediately available.

Take necessary precautions if you use drugs

Health Canada is urging Canadians to treat all illegal drugs as potentially contaminated and to take the necessary precautions if they are using drugs, such as:

In the event of an overdose:

Don't be afraid to seek emergency help if you or someone you are with is experiencing overdose-like symptoms. Canada's Good Samaritan Drug Overdose Act protects individuals who seek emergency help for an overdose from charges of simple possession, as well as breach of conditions related to simple possession as it relates to pre-trial release, probation order, conditional sentence or parole.

Help is available if you, a friend or a family member are struggling with a substance use disorder.

Limitations of Test Strips in Detecting Fentanyl

Canada is currently facing a public health crisis because of an increasing number of opioid-related overdoses. Health Canada is aware that some individuals and organizations may choose to use test strips to detect fentanyl, as part of harm reduction measures.

Some individuals and organizations are using test strips to detect fentanyl by dissolving a small amount of drugs in a solution. These test strips have not been designed for direct use by consumers in this way, which could lead to false negative results.

Health Canada's Drug Analysis Service has undertaken a preliminary study to compare the accuracy of a fentanyl test strip product against our more accurate laboratory technology. Results to date are very preliminary, but do show that there is a possibility for a small number of false negatives. More research on this issue is needed.

Health Canada is committed to investing in research to improve drug-checking technologies, and to inform on-going discussions on this harm reduction practice. Health Canada will also continue to support access to drug-checking services at approved supervised consumption sites that wish to provide this service, where individuals have access to personnel who are trained in overdose response.

Également disponible en français

 

SOURCE Health Canada


These press releases may also interest you

at 05:12
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme"). For this purpose, Sobi has prepared a base prospectus, which...

at 04:00
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood pressure screening and promote hypertension prevention, detection,...

at 02:48
Today, RaySearch Laboratories AB (publ)  publishes its Annual Report for the financial year 2023. The report is held available on RaySearch's website, under the section Investors.  This information is information that RaySearch Larboratiories AB...

at 02:43
Shareholders of Zinzino AB (publ) are hereby invited to the annual general meeting on Monday, May 27, 2024, at 1:30 PM at the company's premises at Hulda Mellgrens gata 5 in Gothenburg. Registration begins at 1:15 PM. The company aims to webcast the...

at 02:41
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website. "Implantica had a very...

at 02:08
Revenue amounted to ?498.8m (?419.3m), an increase of 18.9% with an organic growth of 14.2%.Operating profit (EBIT) was ?19.0m (?10.7m), an increase of 78.0%, representing an operating margin of 3.8% (2.6%).Net profit amounted to ?6.5m (?2.1m), which...



News published on and distributed by: